### ICMJE DISCLOSURE FORM

Date: Feb 17, 2022 Your Name: Wentao Ji Manuscript Title: Reply to "Is neostigmine safe and effective for neuromuscular blockade reversal in patients recovering from general anesthesia? Manuscript number (if known): ATM-2022-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone
	manuscript writing or educational events	
6	Payment for expert	X None
Ū	testimony	
	,	
7	Support for attending	_ <b>X</b> None
	meetings and/or travel	
8	Patents planned, issued or	X None
	pending	
9	Participation on a Data	_ XNone
	Safety Monitoring Board or	
10	Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy	_ XNone
	group, paid or unpaid	
11	Stock or stock options	X None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ <b>X</b> None

### Please summarize the above conflict of interest in the following box:

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### ICMJE DISCLOSURE FORM

Date: Feb 17, 2022
Your Name: Xiaoting Zhang
Manuscript Title: Reply to "Is neostigmine safe and effective for neuromuscular blockade reversal in patients recovering from general anesthesia?
Manuscript number (if known): ATM-2022-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone
	manuscript writing or educational events	
6	Payment for expert	X None
Ū	testimony	
	,	
7	Support for attending	_ <b>X</b> None
	meetings and/or travel	
8	Patents planned, issued or	X None
	pending	
9	Participation on a Data	_ XNone
	Safety Monitoring Board or	
10	Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy	_ XNone
	group, paid or unpaid	
11	Stock or stock options	X None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ <b>X</b> None

### Please summarize the above conflict of interest in the following box:

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### ICMJE DISCLOSURE FORM

Date: Feb 17, 2022 Your Name: Lulong Bo Manuscript Title: Reply to "Is neostigmine safe and effective for neuromuscular blockade reversal in patients recovering from general anesthesia? Manuscript number (if known): ATM-2022-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ <b>X</b> None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone
	manuscript writing or educational events	
6	Payment for expert	X None
Ū	testimony	
	,	
7	Support for attending	_ <b>X</b> None
	meetings and/or travel	
8	Patents planned, issued or	X None
	pending	
9	Participation on a Data	_ XNone
	Safety Monitoring Board or	
10	Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy	_ XNone
	group, paid or unpaid	
11	Stock or stock options	X None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ <b>X</b> None

### Please summarize the above conflict of interest in the following box:

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.